How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)

Overview

The readmission of Heart Failure (HF) patients for exacerbation HF within 30-day is unmet goal. The mail reason for readmission is excessive accumulation of fluid in patient's lung. According our data (1,2) around 40% of HF patient have excessive lung fluid at discharge from HF hospitalization ("unacceptable" residual congestion on discharge). In other words, around 40% patients are discharged from HF hospitalization prematurely when they are not ready to be discharged. Only 60% of HF patients are discharged from HF admission with "acceptable" level of residual pulmonary congestion (2). There are some techniques to assess "readiness" of HF patients for discharge. Pulmonary congestion (lung fluid accumulation) may be assessed non-invasively by measurement Brain Natriuretic Peptide (BNP), (3,4), by lung ultrasound (LUS), (5-7) and by Lung Impedance (LI) method (1,2). LUS is operator depended technique. LI and BNP techniques are most reliable methods (2) and easy to use.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2021

Interventions

  • Diagnostic Test: Lung Impedance Device
    • The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
  • Drug: Anti-congestive treatment
    • Continuation of in-hospital anti-congestive treatment

Arms, Groups and Cohorts

  • Active Comparator: Control Group
    • Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
  • Active Comparator: Interventional Group
    • Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.

Clinical Trial Outcome Measures

Primary Measures

  • Prevention of heart failure re-admission
    • Time Frame: 30 days
    • 30-day re-admission rates will be compared between the two groups
  • Prevention of heart failure re-admission
    • Time Frame: 90 days
    • 90-day re-admission rates will be compared between the two groups

Participating in This Clinical Trial

Inclusion Criteria

  • Acute Heart Failure Patients Prior to Hospital Discharge Exclusion Criteria:

  • No Cardiac Resynchronization Device Implanted During Current Hospitalization – Estimated glomerular filtrating rate (GFR) less than 30 ml/min

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Karina Zilber, MD, Principal Investigator, Hillel Yaffe Medical Center
  • Overall Contact(s)
    • Michael Kleiner Shochat, MD, PhD, 972-50-6246926, shochat1@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.